PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EXAS vs. DXCM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EXAS and DXCM is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

EXAS vs. DXCM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exact Sciences Corporation (EXAS) and DexCom, Inc. (DXCM). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%60.00%AugustSeptemberOctoberNovemberDecember2025
14.50%
-22.20%
EXAS
DXCM

Key characteristics

Sharpe Ratio

EXAS:

-0.28

DXCM:

-0.57

Sortino Ratio

EXAS:

-0.03

DXCM:

-0.41

Omega Ratio

EXAS:

1.00

DXCM:

0.92

Calmar Ratio

EXAS:

-0.23

DXCM:

-0.52

Martin Ratio

EXAS:

-0.73

DXCM:

-0.92

Ulcer Index

EXAS:

23.13%

DXCM:

34.46%

Daily Std Dev

EXAS:

59.13%

DXCM:

55.04%

Max Drawdown

EXAS:

-98.01%

DXCM:

-94.61%

Current Drawdown

EXAS:

-64.65%

DXCM:

-46.51%

Fundamentals

Market Cap

EXAS:

$10.14B

DXCM:

$34.02B

EPS

EXAS:

-$1.16

DXCM:

$1.65

PEG Ratio

EXAS:

-1.07

DXCM:

1.35

Total Revenue (TTM)

EXAS:

$2.05B

DXCM:

$2.92B

Gross Profit (TTM)

EXAS:

$1.47B

DXCM:

$1.78B

EBITDA (TTM)

EXAS:

$14.62M

DXCM:

$671.70M

Returns By Period

In the year-to-date period, EXAS achieves a -2.49% return, which is significantly lower than DXCM's 11.98% return. Over the past 10 years, EXAS has underperformed DXCM with an annualized return of 7.29%, while DXCM has yielded a comparatively higher 19.70% annualized return.


EXAS

YTD

-2.49%

1M

-7.03%

6M

14.50%

1Y

-16.55%

5Y*

-9.40%

10Y*

7.29%

DXCM

YTD

11.98%

1M

9.49%

6M

-22.20%

1Y

-31.49%

5Y*

8.32%

10Y*

19.70%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EXAS vs. DXCM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXAS
The Risk-Adjusted Performance Rank of EXAS is 3131
Overall Rank
The Sharpe Ratio Rank of EXAS is 3131
Sharpe Ratio Rank
The Sortino Ratio Rank of EXAS is 3131
Sortino Ratio Rank
The Omega Ratio Rank of EXAS is 3131
Omega Ratio Rank
The Calmar Ratio Rank of EXAS is 3232
Calmar Ratio Rank
The Martin Ratio Rank of EXAS is 3030
Martin Ratio Rank

DXCM
The Risk-Adjusted Performance Rank of DXCM is 1919
Overall Rank
The Sharpe Ratio Rank of DXCM is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of DXCM is 2121
Sortino Ratio Rank
The Omega Ratio Rank of DXCM is 1717
Omega Ratio Rank
The Calmar Ratio Rank of DXCM is 1515
Calmar Ratio Rank
The Martin Ratio Rank of DXCM is 2525
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EXAS vs. DXCM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Exact Sciences Corporation (EXAS) and DexCom, Inc. (DXCM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EXAS, currently valued at -0.28, compared to the broader market-2.000.002.004.00-0.28-0.57
The chart of Sortino ratio for EXAS, currently valued at -0.03, compared to the broader market-4.00-2.000.002.004.006.00-0.03-0.41
The chart of Omega ratio for EXAS, currently valued at 1.00, compared to the broader market0.501.001.502.001.000.92
The chart of Calmar ratio for EXAS, currently valued at -0.23, compared to the broader market0.002.004.006.00-0.23-0.52
The chart of Martin ratio for EXAS, currently valued at -0.73, compared to the broader market0.0010.0020.0030.00-0.73-0.92
EXAS
DXCM

The current EXAS Sharpe Ratio is -0.28, which is higher than the DXCM Sharpe Ratio of -0.57. The chart below compares the historical Sharpe Ratios of EXAS and DXCM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.00AugustSeptemberOctoberNovemberDecember2025
-0.28
-0.57
EXAS
DXCM

Dividends

EXAS vs. DXCM - Dividend Comparison

Neither EXAS nor DXCM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EXAS vs. DXCM - Drawdown Comparison

The maximum EXAS drawdown since its inception was -98.01%, roughly equal to the maximum DXCM drawdown of -94.61%. Use the drawdown chart below to compare losses from any high point for EXAS and DXCM. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%AugustSeptemberOctoberNovemberDecember2025
-64.65%
-46.51%
EXAS
DXCM

Volatility

EXAS vs. DXCM - Volatility Comparison

Exact Sciences Corporation (EXAS) has a higher volatility of 14.07% compared to DexCom, Inc. (DXCM) at 10.14%. This indicates that EXAS's price experiences larger fluctuations and is considered to be riskier than DXCM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%AugustSeptemberOctoberNovemberDecember2025
14.07%
10.14%
EXAS
DXCM

Financials

EXAS vs. DXCM - Financials Comparison

This section allows you to compare key financial metrics between Exact Sciences Corporation and DexCom, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab